Index

Note: Page numbers of article titles are in **boldface** type.

A

*N*-Acetylcysteine
for malaria, 234

Acidosis
in malaria
management of, 227–228

Acquired immunodeficiency syndrome (AIDS)
travelers with, 36–39

Acute lung injury
in malaria
management of, 228–229

Acute myocardial infarction
in expatriates in Ghana, 86–89

Acute renal failure
in malaria
management of, 230–231

Acute respiratory distress syndrome (ARDS)
in malaria
management of, 228–229

African trypanosomiasis
from Tanzania
detection of, 10–11
HIV infection and, 126–128

Age
as factor in adverse effects of yellow fever vaccine, 156
as factor in malaria in travelers, 213

AIDS. See *Acquired immunodeficiency syndrome (AIDS)*.

Air travel. See also *Air travelers.*
crib death due to, 78
during pregnancy, 79–80
sickness due to, 79

Air travelers. See also *Air travel.*
aspirin use by, 74–75
cardiovascular problems in automated external defibrillators for, 73–75
child safety seats for, 77

face masks for, 67–69
health risks to, 67–84
peanuts, 75–77
travel delay recommended for, 72–73
in-flight oxygen for, 69–72
SARS in, 68
tuberculosis in, 69

Amphotericin B
for cutaneous leishmaniasis in returning travelers, 257

Anemia
in malaria
management of, 231–232

Antigen(s)
fecal
in diagnostic parasitology, 269
malaria
in diagnostic parasitology, 269

Antigen detection ELISA
in diagnostic parasitology, 269

Antimalarial(s)
for severe malaria in travelers, 222–226

Anti–tumor necrosis factor
for malaria, 233–234

ARDS. See *Acute respiratory distress syndrome (ARDS).*

Arthropod(s)
as vectors, 170
direct injury due to, 170
of medical importance nonparasitic, 179
parasites
of humans, 174–176
larvae, 176–177
nest parasites, 177–178
ticks, 176
of momentary duration, 178–179
pre- and post-trip considerations related to, 179–182
travel medicine guide to, 169–183
Arthropod(s) (continued)
transmission of, 170–171
modes of, 171–174

Aspirin
for air travelers, 74–75

Asplenia
travelers with, 39–43

Atovaquone-proguanil
in malaria prevention in travelers, 188–192

Automated external defibrillators
for air travelers, 73–74

Azithromycin
in malaria prevention in travelers, 199–201

B
Blackwater fever
in malaria
management of, 230

Blindness
intermittent
with 24-hour history of acute psychosis
in climber case example, 96–99

Blood film examination
in malaria in travelers, 217–218

Breast-feeding
by pregnant travelers, 35–36

C
Cancer chemotherapy survivors
traveling by, 39–43

Cardiovascular problems
in air travelers
automated external defibrillators for, 73–74

Cerebral malaria
management of, 226–227

Chagas’ disease
HIV infection and, 128

Chemoprophylaxis
in malaria prevention in travelers, 187–188, 214

Child safety seats
for air travel, 77

Children
young
traveler’s diarrhea in, 25

Chinese immigrants
illegal
falciparum malaria
detection of, 11

Chloroquine
in malaria prevention in travelers, 187, 188

Climber(s)
intermittent blindness with 24-hour history of acute psychosis in case example, 96–99

Condom(s)
in STD reduction in travelers, 111–112

Convulsion(s)
in malaria
management of, 227

Counseling
for travelers visiting friends and relatives in developing countries, 51–52

Crib death
air travel and, 78

Cutaneous leishmaniasis
in returning travelers, 241–266
clinical presentation of, 245–247
diagnosis of, 247–248
epidemiology of, 244–245
future developments in, 260–261
mucosal leishmaniasis, 248–249
personal perspective on, 259–260
treatment of, 249–259

amphotericin B in, 257
drugs in, 251
fluconazole in, 255
intralesional injections, 254–255
itraconazole in, 255
drug agents in, 256–257
local vs. systemic, 251–253
oral agents in, 255–256
parasite strain in, 250–251
parental agents in, 256–257
physical methods, 253–254
SSG in, 256–257
topical, 254

D
Defibrillator(s)
automated external
for air travelers, 73–74
Dengue fever
travel health risks associated with surveillance of, 5–6

Developing countries
travelers visiting friends and relatives in disease prevention in, 49–65.
See also Traveler(s), visiting friends and relatives in developing countries.
 risk assessment for, 49–65.
See also Traveler(s), visiting friends and relatives in developing countries.

Diabetes mellitus
in travelers, 30–32

Dialysis
renal for malaria, 233

Diarrhea
traveler’s, 137–149. See also Traveler’s diarrhea.

Dichloroacetate
for malaria, 234

Dipstick tests
for malaria in travelers, 204

Disease(s)
imported travel health risks related to surveillance of, 1–13. See also Travel health risks, imported diseases and.

Dominican Republic
falciparum malaria in detection of, 8–10

Drug resistance
in malaria prevention in travelers, 187–188

Exchange transfusion
for malaria, 232–233

Expatriate(s)
in Ghana acute myocardial infarction in, 86–89
international emergency and medical evacuation for case examples of, 85–101 pretravel screening tests in, 88

F
Face masks
for air travelers, 67–69

Falciparum malaria
in Dominican Republic detection of, 8–10 in illegal Chinese immigrants detection of, 11 pathogenesis of, 212–213

Fecal antigen detection RDTs
in diagnostic parasitology, 268

Fecal antigens
in diagnostic parasitology, 269

Fever
typhoid in travelers visiting friends and relatives in developing countries, 55–56 yellow. See Yellow fever.

Filariasis
lymphatic HIV infection and, 130–131

Fluconazole
for cutaneous leishmaniasis in returning travelers, 255

Fluid and electrolyte disturbances
in malaria management of, 230

Fluid overload
in malaria management of, 228

E
Economy class syndrome, 74

Elderly
current traveling with, 26–30. See also Traveling, with the elderly.

ELISA
antigen detection in diagnostic parasitology, 269

Encephalitis
Japanese. See Japanese encephalitis.

G
Gender as factor in malaria in travelers, 213

Genetic resistance and susceptibility as factor in malaria in travelers, 213–214
Geologic engineers
fever, malaise, and rapidly spreading
lesion in
case example, 92–96
Ghana
expatriates in
acute myocardial infarction in,
86–89

H
Helminth(s)
intestinal
HIV infection and, 131–132
Hemofiltration
for malaria, 233
Hemostatis disorders
in malaria
management of, 231
Hepatitis
A
in travelers visiting friends and
relatives in developing
countries, 55
B
in travelers visiting friends and
relatives in developing
countries, 53–54
HIV. See Human immunodeficiency virus
(HIV).
HIV infection. See Human immunodeficiency
virus (HIV) infection.
Human(s)
parasites of, 174–176
Human African trypanosomiasis
HIV infection and, 126–128
Human immunodeficiency virus (HIV) infection
in travelers, 36–39
medication adherence in, 112–113
tropical diseases effects of, 121–135
Chagas’ disease, 128
human African trypanosomiasis,
126–128
intestinal helminths, 131–132
leishmaniasis, 123–126
liasis, 130–131
lymphatic filariasis, 130–131
malaria, 122–123
onchocerciasis, 130
schistosomiasis, 128–130
Hyperparasitemia
in malaria
management of, 231
Hypoglycemia
in malaria
management of, 229
Hypotension
in malaria
management of, 229–230

I
Illegal immigrants
Chinese
falciparum malaria in
detection of, 11
Immunity
acquired
pre-existing
as factor in malaria in
travelers, 214
Immunization(s)
for travelers
children, 17–21
elderly, 27–29
pregnant, 34
Immunofluorescence-based fecal
microscopy
in diagnostic parasitology, 269
Imported diseases
tavel health risks related to
surveillance of, 1–13. See also
Travel health risks, imported
diseases and.
Infection(s). See also specific types.
secondary
in malaria
management of, 229
In-flight oxygen
for air travelers, 69–72
International Airlines Transport
Association, 73
International emergency and medical
evacuation procedures
for expatriates, refugees, disaster relief
workers, and Peace Corps
volunteers, 85–101. See also
specific group, e.g.,
Expatriate(s).
Intestinal helminths
HIV infection and, 131–132
Iron chelators
for malaria, 234
Itraconazole
for cutaneous leishmaniasis in
returning travelers, 255
Japanese encephalitis, 157–166
  described, 157–159
  travelers’ risk for, 163–164
  vaccine for
    adverse effects of, 161–163
    described, 159–160
    for travelers, 165–166
    neurologic disease associated with, 162–163

Ketoconazole
  for cutaneous leishmaniasis in returning travelers, 255

Larva(ae)
  duration of stay of, 176–177
Leishmania RDTs
  in diagnostic parasitology, 268
Leishmaniasis(es)
  cutaneous
    in returning travelers, 241–266.
    See also Cutaneous leishmaniasis, in returning travelers.
    described, 241–244
    geographic distribution of, 241–242
    HIV infection and, 123–126
    life cycle of, 242
    mucosal
      in returning travelers, 248–249
    taxonomy of, 242–244
Liaisis
  HIV infection and, 130–131
Lung injuries
  acute
    in malaria
      management of, 228–229
Lymphatic filariasis
  HIV infection and, 130–131

Malaria
cerebral
  management of, 226–227
falciparum. See Falciparum malaria.
  HIV infection and, 122–123
  in travelers
    age and, 213
    chemoprophylaxis and, 214
    elderly, 29
  epidemiology of, 185–186, 211–212
  features of, 213–215
  gender and, 213
  genetic resistance and susceptibility and, 213–214
  in developing countries, 57–59
  pre-existing acquired immunity and, 214
  pregnant, 34–35
  prevention of, 185–210
    atovaquone-proguanil in, 188–192
    azithromycin in, 199–201
    chemoprophylaxis in, 187–188
    drug resistance in, 187–188
    personal protective measures in, 204–205
    primaquine in, 192–195
    standby treatment in, 201–204
    surveillance strategies in, 186–187
    tafenoquine in, 195–199
  rapid diagnostics for, 204
  relief workers with, 89–92
  severe
    acidosis in
      management of, 227–228
    acute lung injury in
      management of, 228–229
    acute renal failure in
      management of, 230–231
    anemia in
      management of, 231–232
    ARDS in
      management of, 228–229
    blackwater fever
      management of, 230
    convulsions in
      management of, 220
    fluid and electrolyte disturbances in
      management of, 230
    fluid overload in
      management of, 228
    hemostasis disorders in
      management of, 231
    hyperparasitemia in
      management of, 231
    hypoglycemia in
      management of, 229
Malaria (continued)

- Hypotension in management of, 229–230
- in travelers
  - antimalarials for, 222–226
  - blood film examination in, 217–218
  - clinical presentations of, 215–216
  - diagnosis of, 217–218
  - differential diagnosis of, 216–217
  - low clinical suspicion and, 214–215
  - management of, 218–222
  - underlying disorders and, 214
  - respiratory distress in management of, 227
  - respiratory tract infection in management of, 228
  - secondary infections in management of, 229
  - shock in management of, 229–230
  - splenic rupture in management of, 232
  - treatment of, 211–240
- N-acetylcysteine in, 234
- anti–tumor necrosis factor measures in, 233–234
- dichloroacetate in, 234
- exchange transfusion in, 232–233
- hemofiltration in, 233
- iron chelators in, 234
- mechanical ventilation in, 233
- pentoxifylline in, 233–234
- renal dialysis in, 233
- travel health risks associated with surveillance of, 3–5
- traveling with young children and, 21–25
- treatment of, 211–240

Malaria antigens
  - in diagnostic parasitology, 269

Malaria RDTs
  - in diagnostic parasitology, 268

Mechanical ventilation
  - for malaria, 233

Mefloquine
  - in malaria prevention in travelers, 187

Microscopy
  - fecal immunofluorescence-based in diagnostic parasitology, 269

Mucosal leishmaniasis
  - in returning travelers, 248–249

Myocardial infarction
  - acute in expatriates in Ghana, 86–89

N

- Nest parasites, 177–178

Neurologic disease
  - Japanese encephalitis vaccine–related, 162–163
  - yellow fever vaccine–related, 154

Nonxynol-9
  - in STD reduction in travelers contraindications to, 112

O

- Onchocerciasis
  - HIV infection and, 130

Oxygen
  - in-flight for air travelers, 69–72

P

- Parasite(s)
  - duration of stay of, 176–177
    - human, 174–176
    - nest, 177–178
    - of momentary duration, 178–179

Parasitology
  - new diagnostics in, 1–4
    - antigen detection ELISA, 269
    - fecal antigen detection RDTs, 268
    - for *Wucheria bancrofti* infection, 268
    - immunofluorescence-based fecal microscopy, 269
    - leishmaniasis RDTs, 268
    - malaria RDTs, 268
    - PCR, 269–270
    - rapid diagnostics, 268
    - RDTs, 268
PCR. See Polymerase chain reaction (PCR).

Peanut(s) allergy to in air travelers, 75–77

Pentoxifylline for malaria, 233–234

Polymerase chain reaction (PCR) in diagnostic parasitology, 269–270

Pre-existing acquired immunity as factor in malaria in travelers, 214

Pregnancy air travel during, 79–80
traveling during, 32–36
breast-feeding and, 35–36
immunizations for, 34
malaria and, 34–35
precautions for, 33–34
traveler’s diarrhea and, 35

Primaquine in malaria prevention in travelers, 187, 192–195

Proguanil in malaria prevention in travelers, 187

Psychosis(es) acute climber with intermittent blindness and 24-hour history of case example, 96–99

Rapid diagnostic tests (RDTs) in diagnostic parasitology, 268

RDTs. See Rapid diagnostic tests (RDTs).

Relief workers malaria in, 89–92
schistosomiasis in, 89–92

Renal dialysis for malaria, 233

Renal failure acute in malaria management of, 230–231

Respiratory distress in malaria management of, 227

Respiratory tract infection in malaria management of, 228

Rupture splenic in malaria management of, 232

S Safety of elderly traveling, 27

SARS. See Severe acute respiratory syndrome (SARS).

Schistosomiasis HIV infection and, 128–130
relief workers with, 89–92

Secondary infections in malaria management of, 229

Seizure disorders travelers with, 43–44

Severe acute respiratory syndrome (SARS) air travel and, 68

Sex as factor in malaria in travelers, 213

Sexual tourism, 103–120

Sexually transmitted diseases (STDs) in travelers experiences of, 113–116
risk assessment for before travel, 107–113
risk-reduction behavior related to condoms, 111–112
educational messages related to, 110–111
nonxynol-9 contraindications to, 112
screening tests for before travel, 107–113
teach and connections between, 104–107, 116–117

Shock in malaria management of, 229–230

Splenic rupture in malaria management of, 232

STDs. See Sexually transmitted diseases (STDs).
Tafenoquine in malaria prevention in travelers, 195–199

Tanzania African trypanosomiasis from detection of, 10–11

T_{H1}-T_{H2} balance review of, 124–125

Thymus disease yellow fever vaccine and, 157

Tick(s) duration of stay of, 176

Tourism sexual, 103–120

Transformation(s) exchange for malaria, 232–233

Transplantation(s) travelers with, 39–43

Travel STDs and, 104–107, 116–117

Travel clinic challenging scenarios in, 15–47
cancer chemotherapy survivors, 39–43
diabetic travelers, 30–32
pregnant travelers, 32–36
transplant-recipient travelers, 39–43
travelers with asplenia, 39–43
travelers with HIV and AIDS, 36–39
travelers with seizure disorders, 43–44
traveling with the elderly, 26–30
traveling with young children, 16–26

Travel delay recommendations health risks and, 72–73

Travel health risks imported diseases and African trypanosomiasis from Tanzania, 10–11
dengue fever, 5–6
falciparum malaria
in Dominican Republic, 8–10
in illegal Chinese immigrants, 11
malaria, 3–5
risk estimates, 6–8
sentinel events detection in, 8–11
surveillance of, 1–13
systematic observations of, 3–6

Travel medicine guide to arthropods of medical importance, 169–183. See also Arthropod(s), of medical importance.

Traveler(s) air health risks to, 67–84. See also Air travelers, health risks to.
complex advice for, 15–47. See also Travel clinic, challenging scenarios in.
diabetic, 30–32
HIV infection in, 112. See also Sexually transmitted diseases (STDs).
Japanese encephalitis in risk factors for, 163–164
vaccine for, 165–166
malaria in. See Malaria, in travelers.
pregnant, 32–36
returning cutaneous leishmaniasis in, 241–266. See also Cutaneous leishmaniasis, in returning travelers.
visiting friends and relatives in developing countries disease prevention in, 49–65
new approach to counseling in, 51–52
hepatitis A in, 55
hepatitis B in, 53–54
high-risk diseases in, 53–61
malaria in, 57–59
morbidity associated with, 50–51
risk assessment for, 49–65
general recommendations, 52–53
routine childhood vaccine–preventable diseases in, 53
tuberculosis in, 59–61
typhoid fever in, 55–56
varicella in, 56–57

Traveler’s diarrhea, 137–149
causes of, 142–143
diagnosis of, 143–144
in pregnant travelers, 35
in the elderly, 29
in young children, 25
prevention of nonantibiotic methods in, 142
personal hygiene precautions in, 139–141
vaccines in, 146
treatment of, 144–145

Traveling
with the elderly, 26–30
immunizations for, 27–29
malaria, 29
safety of, 27
traveler’s diarrhea in, 29
with young children, 16–26
immunizations, 17–21
malaria, 21–25
preparation for, 17
traveler’s diarrhea, 25

Tropical diseases
HIV infection effects on, 121–135. See also Human immunodeficiency virus (HIV) infection, tropical diseases effects of.

Trypanosomiasis
African from Tanzania
detection of, 10–11
HIV infection and, 126–128

Tuberculosis
in air travelers, 69
in travelers visiting friends and relatives in developing countries, 59–61

Typhoid fever
in travelers visiting friends and relatives in developing countries, 55–56

V
Vaccine(s)
for traveler’s diarrhea, 146
for yellow fever, 151–157. See also Yellow fever, vaccine for.

Varicella
in travelers visiting friends and relatives in developing countries, 56–57

Ventilation
mechanical
for malaria, 233

Viscerotropic disease
yellow fever vaccine–related, 154–155

W
Wucheria bancrofti infection
RDTs for, 268

Y
Yellow fever
described, 151–153
vaccine for, 151–157
adverse effects of, 153–155
age-related, 156
risks factors for, 156–157
described, 153
neurologic disease associated with, 154
thymus disease associated with, 157
viscerotropic disease associated with, 154–155